S
ystemic autoimmunity is characterized by widespread inflammation, autoantibody production and immune complex deposition. The regulatory mechanisms for the systemic autoimmunity are not fully understood. A paper by Li et al. revealed that Egr2 and Egr3, transcription factors required for T-cell anergy, are the regulators for systemic autoimmune disease. They showed evidence that Egr2 and Egr3 control cytokine productions and cell proliferation via SOCS and Batf regulation.
T-cell anergy is one important mechanism for immune tolerance. In CD4 + T cells, it was reported that Egr2 and Egr3 are required for anergy induction.
1,2 Egr2 and Egr3 are the members of Cys 2 His 2 -type zinc finger transcription factor family, which consists of four members, Egr1, 2, 3 and 4. Egr2 plays an essential role in hindbrain development and myelination of the peripheral nervous system, and the null mutation of Egr2 resulted in perinatal or neonatal death due to respiratory and/or feeding deficits.
3 Egr3-deficient mice show gait ataxia due to the lack of muscle spindles. 4 Egr2 and Egr3 inhibit interferon (IFN)-γ and IL-2 secretion by T cells and enhance the expression of the E3 ligase Cbl-b, which is critical for the regulation of T cell tolerance and anergy. Recently, it has been reported that deletion of JunB in epithelial cells results in skin inflammation that is similar to systemic lupus erythematosus (SLE) with increased serum proinflammatory cytokines and a myeloproliferative disorder. 12 Therefore, the fact that 13 These observations indicate that Egr2 and Egr3 are key candidate transcription factors to control systemic autoimmunity. The linkage between Egr2 and lupus was also suggested by the observation that EGR2 is a risk factor for SLE in a case-control association study.
14 Moreover, silencing of Batf in Egr2-and Egr3-deficient CD4 + T cells reduced expression of IL-17, consistent with previous findings on the role of Batf in IL-17 expression. 11 This study is important in elucidating the role of Egr2 and Egr3 in systemic autoimmunity. Nevertheless, it systemic autoimmune disease was lethal and developed in their early life, and both Th1 and Th17 cell-derived cytokines excessively accumulated. The suppression of both SOCS1 and SOCS3 is supposed to be the cause of their severe inflammatory pathological phenotype. The direct regulation of both SOCS1 and SOCS3 expression by Egr2 suggests that the role of Egr2 and Egr3 is vital for preventing autoimmune diseases, and limiting immunopathology during productive immune responses.
In Egr2-and Egr3-deficient B and T cells, electrophoretic mobility shift assay (EMSA) analysis revealed the severe impairment of the activation of AP-1, an essential transcription factor for the production of IL-2 and cell cycle progression. Instead, an alternative molecular complex involving JunB, not c-Fos, was detected. Therefore, Batf, a member of the AP-1 complex that forms a heterodimer with c-Jun or JunB, was supposed to be a part of the alternative AP-1 complex.
11 While Egr2 and Egr3 did not regulate Batf transcription, the binding of Egr2 to Batf blocked the association of Batf to AP-1 DNA probe. These findings indicated that Egr2 and Egr3 support AP-1 activation by the suppression of Batf function (Fig. 2) . It was an unexpected observation that Egr2 and Egr3 positively regulate antigen receptor induced proliferation because Egr2 and Egr3 have been regarded as negative regulators of T cell receptor signaling. 2 However, suppression
Egr3-deficient CD4 + T cells. As antigen receptor signaling did not display hyperactivation in CD2-Egr2 −/− Egr3 −/− mice, enhancement of cytokine receptor signaling became another candidate pathway for the enhanced activation. In the stimulated Egr2-and Egr3-deficient B and T cells, both STAT1 and STAT3, not STAT5 were significantly activated, and expression of SOCS1 and SOCS3 was significantly reduced. Chromatin immunoprecipitation (ChIP) assay demonstrated direct binding of Egr2 to SOCS1 and SOCS3 promoters, and luciferase reporter assay showed that Egr2 induces SOCS1 and SOCS3 promoter activity. From these findings, it was concluded that Egr2 and/or Egr3 directly induce SOCS1 and SOCS3 expression, and it leads to the suppression of STAT1-and STAT3-mediated cytokine signaling (Fig. 1) .
SOCS1 and SOCS3 are suppressors of STAT1 and STAT3 activation, and they essentially regulate the STAT1-and STAT3-mediated cytokine expression and the differentiation of Th1 and Th17 cells.
7 Although SOCS1-deficient T cells shift to Th1 cell differentiation and produce IFN-γ in the absence of TCR ligation, 8 T cell-specific SOCS1 deficient mice do not develop spontaneous inflammatory pathologies, and their T cells are resistant to Th17 cell differentiation. 9 On the other hand, SOCS3-deficient T cells are more susceptible to Th17 cell differentiation, but resistant to Th1 cell differentiation. 10 In CD2-Egr2 −/− Egr3 −/− mice, 16 Thus, Egr2 could be the regulatory transcription factor controlling multiple aspect of inflammatory response, and the precise contribution of Egr2 and Egr3 expressed in helper T cells, Tregs or B cells should be addressed in the future.
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